FDA, Duke-Margolis workshop to examine evidence standards for rare diseases

Summary

The FDA and Duke-Margolis are organizing a workshop to examine evidence standards for rare diseases. This is a routine regulatory discussion initiative with no immediate impact on specific drug approvals or companies.